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LETTERS TO THE EDITOR
Stable creatinine clearance
using large-dose HES versus
reduced GFR
To the editor: In a recent issue of Kidney Interna-
tional, Winkelmayer et al [1] reported postoperative renal
impairment after a relatively low dose of hydroxyethyl
starch (HES) 670/0.75 in patients with coronary artery
bypass graft (CABG). These data should be compared
with data from a randomized clinical trial recently pub-
lished by our group [2], which do not support the find-
ings by Winkelmayer et al, but in fact show preserved
renal function when a novel HES 130/0.4 specification
was administered in repetitive large doses in patients with
head injury. In addition, a study of Jungheinrich et al [3]
in volunteers with mild-to-severe renal impairment did
not reveal further deterioration of renal function after a
single HES 130/0.4 dose. These contrasting findings do
not surprise. Each different HES solution has its specific
physicochemical properties (molar substitution [MS],
pattern of hydroxyethylation [C2:C6 ratio], mean molec-
ular weight [Mw]) that determine the in vivo character-
istics. Unfavorable in vivo characteristics of mainly older
HES products with high Mw and high MS (hetastarches,
e.g., HES 450/0.7) are known to cause plasma accumula-
tion of macromolecules [4], which has been attributed to
impaired renal function and blood coagulation. There-
fore, physicochemical characteristics of new generation
HES solutions, such as HES 130/0.4, have been modified
and result in negligible plasma accumulation, preserved
renal function, and blood coagulation. Because physic-
ochemical characteristics appear to be critical to patient
safety we suggest that properties of HES products should
be considered before their use in the clinical setting, and
that findings with certain HES types must not be gener-
alized for other HES solutions.
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Reply from the Authors
Drs. Neff and Stocker point out that different prepa-
rations of hydroxyethyl starch (HES) might differ with
regard to their biologic actions, which is compatible with
our findings.They provide data from two manufacturer-
funded studies of a novel HES 130/0.4 product to support
the claim that HES (130/0.4) preserved renal function
in a randomized clinical trial. The cited study was con-
ducted in trauma patients randomized to either receive
HES (130/0.4) or HES (200/0.5) plus human albumin.
While there was no difference in renal function (mea-
sured by creatinine clearance) between the two regimens
during follow-up, the authors failed to disclose renal func-
tion at baseline, so that change of renal function cannot
be judged from the article. Also, the number of patients
studied was small (N = 15 + 16), so that the power to
detect any meaningful differences between these groups
was limited. We performed a power calculation of that
study (assuming a = 0.05, and SD = 20 mL/min) and
found that its power to detect a between-group difference
of 7 mL/min was only 15%, and only 9% for a within-
group comparison. The same argument pertains to the
second study they cite (N = 19), which was conducted
in volunteers with stable renal function, a setting that is
probably not representative of a surgery or intensive care
situation. The data from the studies cited are therefore
of very limited use regarding a possible association be-
tween HES use and renal function. While different HES
preparations may have different effects on renal function,
unless this is shown in a sufficiently well powered study,
the concern of adverse outcomes in HES recipients re-
mains unresolved.
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